Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib
Alisertib is identified as a potent enhancer of Donafenib-induced ferroptosis through inhibition of the NF-κB/NRF2 pathway. This suggests a novel combinatorial strategy that targets ferroptosis through NF-κB inhibition. Further research is needed to translate these promising results into clinical practice.
Authors
- Qiong Zhou (ORCID: https://orcid.org/0009-0007-7515-0256)
- Rui Wang (ORCID: https://orcid.org/0000-0001-7745-9221)
Institutions
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.3389/fcell.2025.1637767
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52